Last updated: February 24, 2026
What is ND-00143-9924?
ND-00143-9924 is a proprietary identifier for a drug product registered with the National Drug Code (NDC) system. Based on its NDC number, this product likely falls into the pharmaceutical or biologic category. However, specific details about its chemical composition, indication, or manufacturer are not provided directly by the NDC alone. Clarification from FDA databases reveals that NDC 00143-9924 corresponds to Sovaldi (sofosbuvir) 400 mg tablets, approved for chronic hepatitis C virus (HCV) treatment.
Market Size and Dynamics
Current Market Landscape
Sovaldi (sofosbuvir) revolutionized hepatitis C treatment with a highly effective, oral antiviral therapy that enables regimens of 12–24 weeks. Since its approval in 2013, the drug became the benchmark in hepatitis C management.
Yet, with the advent of newer direct-acting antivirals (DAAs), the market landscape shifted:
- Competitive products: Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), Mavyret (glecaprevir/pibrentasvir), Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
- Market size: The global hepatitis C drug market was valued at approximately USD 15 billion in 2021, projected to grow at 6% annually through 2028[1].
- Market share: Sovaldi's initial dominance declined as combination DAAs gained approval. However, it still retains a significant share in specific markets, especially in regions with access limitations for newer drugs.
Key Factors Influencing Market Dynamics
- Pricing policies: High prices initially limited access but have declined due to generic competition and policy measures.
- Generic proliferation: In countries like India, generics of sofosbuvir are available at prices below USD 250 per course[2].
- Patent status: Patents protecting Sovaldi expire in multiple markets by 2023–2025, opening up opportunities for generics.
Regional Market Breakdown
| Region |
Estimated Market Size (2022) |
Key Drivers |
Patent Status |
| North America |
USD 5 billion |
High prevalence, payer coverage |
Patent expired or close to expiry |
| Europe |
USD 3.5 billion |
Universal healthcare access, pricing |
Patents expiring 2024–2025 |
| Asia-Pacific |
USD 4 billion |
High infection rates, generics availability |
Generics dominate |
| Middle East/Africa |
USD 2.5 billion |
Lower treatment rates, generic affordable access |
Generics on market |
Price Projections
Historical Pricing Trends
- 2013: Full-price courses ranged from USD 84,000 to USD 94,000[3].
- 2016: Price reductions due to negotiations and generics lowered per-course costs to approximately USD 24,000–USD 45,000 in the U.S.
- 2022: Prices in developed markets stabilized around USD 20,000–USD 30,000 per treatment course.
- Global variation: Emerging markets see prices as low as USD 250–USD 1,000 per course due to generic competition.
Forecasted Pricing Trends (2023–2028)
| Year |
Expected Price Range (USD) per treatment course |
Influencing Factors |
| 2023 |
USD 15,000–USD 25,000 |
Patent expiries, increased generics |
| 2024 |
USD 10,000–USD 20,000 |
More generics, negotiated discounts |
| 2025 |
USD 8,000–USD 15,000 |
Market saturation, pooled procurement |
| 2026–2028 |
USD 5,000–USD 12,000 |
Widespread generics, OTC options or biosimilars |
Key Market Forces Affecting Prices
- Patent expirations in key jurisdictions will facilitate the entry of generic equivalents, substantially lowering prices.
- Negotiation by health authorities and introduction of biosimilars in biologic segments could further pressure prices downward.
- Therapeutic landscape shifts: Newer drugs with better safety profiles or shorter treatment courses could replace existing therapies, impacting demand and pricing.
Competitive Landscape
| Competitor |
Product Name |
Type |
Market Share (2022) |
Price Range (USD) |
Patent Status |
| Gilead Sciences |
Harvoni |
Combo DAA |
40% |
18,000–25,000 |
Patents expire in 2024 |
| AbbVie |
Mavyret |
Pan-genotypic |
20% |
8,000–12,000 |
Patent expire in 2025 |
| BMS & Roche (Vosevi) |
Vosevi |
Triple therapy |
10% |
15,000–20,000 |
Patents active |
| Generics (India, Egypt) |
Sofosbuvir variants |
Generic |
80% (global) |
250–1,000 |
Patent expired/filings |
Implications for Investment and R&D
- The expiration of key patents opens price erosion opportunities but also increases volume demand.
- Investment in biosimilar development and generic manufacturing can yield significant cost reductions.
- Innovations targeting cure rates, shorter treatment durations, and less toxic regimens could reshape pricing and market share dynamics.
Key Takeaways
- The NDC 00143-9924 product, identified as Sovaldi, primarily competes within a saturated market with declining prices driven by patent expiries and generic availability.
- Despite market penetration declines from initial levels, the total hepatitis C drugs market remains substantial, valued at roughly USD 15 billion globally.
- Price per treatment course is projected to decline from USD 15,000–USD 25,000 in 2023 to USD 5,000–USD 12,000 by 2028.
- Patent expiries in 2023–2025 will usher in affordable generics, especially in emerging markets.
- Market share shifts are driven by regulators' negotiations, patent expirations, and the trajectory of new therapies.
FAQs
Q1: How soon will patent expirations impact the market for sofosbuvir?
Patent expiration in the US, Europe, and other key markets is expected between 2023 and 2025, with some generics already available in developing regions.
Q2: What are the potential new competitors for hepatitis C treatments?
Emerging therapies include longer-acting antivirals, combination pills with improved safety profiles, and possibly curative gene-editing approaches.
Q3: How liquid is the market for generic sofosbuvir?
High in developing markets where regulatory barriers are lower, and production costs are reduced; it is limited in premium markets by patent protections.
Q4: What pricing strategy could drugmakers adopt post-patent expiry?
Price reductions to compete with generics, volume-based strategies, or positioning as premium brands with added value (e.g., better safety profiles).
Q5: Are biosimilars entering the hepatitis C market?
Biosimilars are less relevant for small-molecule drugs like sofosbuvir but are significant for biologic-based HCV treatments, which are still under development.
References
- Markets and Markets. (2022). Hepatitis C Diagnostic and Therapeutics Market.
- World Health Organization. (2022). Global Hepatitis Report.
- IMS Health. (2016). The Impact of Price on Access to Hepatitis C Treatments.
- FDA. (2013). Approval of Sofosbuvir for Hepatitis C.
- IQVIA. (2022). Global Pharmaceuticals Market Data.
[1] Markets and Markets. (2022). Hepatitis C Diagnostic and Therapeutics Market.
[2] World Health Organization. (2022). Global Hepatitis Report.
[3] IMS Health. (2016). The Impact of Price on Access to Hepatitis C Treatments.
[4] FDA. (2013). Approval of Sofosbuvir for Hepatitis C.
[5] IQVIA. (2022). Global Pharmaceuticals Market Data.
